Simple Summary Nephrotoxicity is the dose-limiting factor of cisplatin treatment.
Nephrotoxicity is characterized by reduced kidney function. Although an often-reversible …

Background Cisplatin (cis-diamminedichloroplatinum II, CDDP) is one of the most effective
chemotherapeutic agents. However, its clinical use is limited due to the severe side effects …

AKI is histologically characterized by necrotic cell death and inflammation. Diverse pathways
of regulated necrosis have been reported to contribute to AKI, but the molecular regulators …

Cisplatin and other platinum derivatives are the most widely used chemotherapeutic agents
to treat solid tumors including ovarian, head and neck, and testicular germ cell tumors. A …

Chronic kidney disease (CKD) is a major public health issue. At the histological level, renal
fibrosis is the final common pathway of progressive kidney disease irrespective of the initial …

Cisplatin is an antitumor drug used in the treatment of a wide variety of malignancies.
However, its primary dose‐limiting side effect is kidney injury, which is a major clinical …

Interleukin 33 (IL-33) is highly expressed in barrier sites, acting via the suppression of
tumorigenicity 2 receptor (ST2). IL-33/ST2 axis has long been known to play a pivotal role in …

Ischemia-reperfusion injury is a major cause of acute kidney injury. Recent studies on the
pathophysiology of ischemia-reperfusion-induced acute kidney injury showed that …

Diabetic kidney disease (DKD) can occur in approximately 30–40% of both type 1 and type
2 diabetic patients. The well-established features of DKD include increased serum glucose …

Acute kidney injury (AKI) is a significant problem in both native and transplant kidneys.
There have been significant advances in understanding the role of immune cells in the early …